Business
Two Year Data on Edwards Lifesciences’ EVOQUE System Continue to Demonstrate Significant and Sustained Patient Benefits
NEW ORLEANS, March 30, 2026--Edwards Lifesciences (NYSE: EW) today announced new data on the EVOQUE transcatheter tricuspid valve replacement (TTVR) system at the American College of Cardiology Annual Scientific Session (ACC.26), demonstrating significant and sustained patient benefits including lower mortality when accounting for patient crossover, extending the findings presented at the European Society of Cardiology Congress (ESC 2025).
About this update from Edwards Lifesciences Corporation
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/214f77648e39e7a7dbfc17e5d2fc7569"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/AwSIPIZjooAFwbvrq9kADA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MA--/https://media.zenfs.com/en/business-wire.com/214f77648e39e7a7dbfc17e5d2fc7569","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/LZvrXDJ_eYDlHwAylWIHDQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0/https://media.zenfs.com/en/business-wire.com/214f77648e39e7a7dbfc17e5d2fc7569","width":1024,"height":512}},"lazy":false},{"type":"text","content":"TRISCEND II randomized trial data presented at ACC show lower mortality with EVOQUE system, when accounting for patient crossover","length":129,"tagName":"p","attribs":{}},{"type":"text","content":"NEW ORLEANS, March 30, 2026--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new data on the EVOQUE transcatheter tricuspid valve replacement (TTVR) system at the American College of Cardiology Annual Scientific Session (ACC.26), demonstrating significant and sustained patient benefits including lower mortality when accounting for patient crossover, extending the findings presented at the European Society of Cardiology Congress (ESC 2025).","length":460,"tagName":"p"},{"type":"text","content":"The new TRISCEND II trial data presented today during a late-breaking featured research session at ACC.26 demonstrated confidence in two-year performance of TTVR with the EVOQUE system and showed:","length":196,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Significant and sustained near elimination of tricuspid regurgitation (TR);","length":75,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Improvements in health status and quality of life;","length":50,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"No added device-related risk; and","length":33,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Significantly lower all-cause mortality when accounting for patient crossover.","length":78,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":236,"olType":false},{"type":"text","content":""There is a significant patient popula...